2025
Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial
Somé A, Somé A, Sougué E, Ouédraogo C, Da O, Dah S, Nikièma F, Magalhaes T, Gray L, Finical W, Pugh G, Lado P, Randall J, Burton T, Ring M, Leon A, Colt M, Li F, Wang K, Wade M, Lier A, Richards K, Sproch H, Zhang E, Ellman J, Achebe I, Jackson C, Xiao M, Wu E, Bousema T, Slater H, Foy B, Parikh S, Dabiré R. Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial. The Lancet Infectious Diseases 2025 PMID: 39919778, DOI: 10.1016/s1473-3099(24)00751-5.Peer-Reviewed Original ResearchSeasonal malaria chemopreventionIvermectin mass drug administrationEntomological inoculation rateMalaria incidenceParallel-group trialMass drug administrationDouble-blindPlacebo-controlledControl groupAdverse eventsPrimary outcomeWeekly active case detectionDrug AdministrationLow malaria incidenceIntervention groupReducing malaria incidenceMalaria-endemic regionsMalaria incidence ratesRisk of adverse eventsInoculation rateNational Institute of AllergyPan African Clinical Trials RegistryComplementary vector control toolsCluster-randomisedInstitute of Allergy
2016
Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children
Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, Li F, Were M, Kakuru A, Achan J, Mwebaza N, Aweeka FT. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Clinical Infectious Diseases 2016, 63: 414-422. PMID: 27143666, PMCID: PMC4946019, DOI: 10.1093/cid/ciw291.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrine treatmentLPV/rRecurrent malariaLumefantrine exposureDrug exposureCritical drug-drug interactionsFirst-line antiretroviral therapy regimensArtemisinin-based combination therapyLopinavir/ritonavirAntiretroviral therapy regimensPlasmodium falciparum malariaHuman immunodeficiency virusDay 7 concentrationsMalaria-endemic regionsDrug-drug interactionsAntimalarial exposureAntimalarial componentPharmacokinetic samplingArtemether-lumefantrineFalciparum malariaClinical outcomesDosing regimensTherapy regimensImmunodeficiency virusCombination therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply